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ABSTRACT 
Human immunodeficiency virus (HIV) is a pandemic that has infected nearly 1% of the 
world population. Despite numerous FDA approved antiviral drugs, HIV drug resistance remains 
a large challenge. HIV protease is an enzyme that is required by the virus to cleave Gag and 
Gag-Pol polyproteins into functional and structural proteins necessary for viral maturation. 
Currently, nine clinical inhibitors target HIV protease, but multiple clinical viral strains have 
developed resistance to these drugs. Therefore, it is necessary to continue developing new drugs 
to tackle the problem of HIV drug resistance, and X-ray crystallography is one tool that is used 
to study how drug candidates bind to HIV-1 protease. In order to study the interactions between 
inhibitor atazanavir and HIV-1 protease, the crystal structure of the complex has been solved at 
atomic resolution (1.09 Å). This structure will improve the design of new inhibitors for resistant 
protease.  
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1 
1 INTRODUCTION  
Human Immunodeficiency Virus (HIV) was transmitted to humans from non-human primates 
via cross-species transmission probably through hunting and butchering bushmeat and perhaps 
through capturing and trading primates and keeping them as pets.1  
1.1 HIV Subtypes  
Over 40 nonhuman primate species harbor species-specific simian immunodeficiency viruses. 
Independent cross-species transmissions have led to multiple HIV lineages. HIV-1 consists of 
groups M, N, O and P and HIV-2 groups A-H. HIV-1 group M is the primary source of the 
global HIV pandemic, and has infected over 33 million individuals, and HIV-1 group O has 
caused a few tens of thousands of infections primarily in West Africa. HIV-1 groups N and P 
have only been identified in a handful of individuals in Cameroon. HIV-1 groups M and N are 
believed to have originated from Pan troglodytes troglodytes in West Africa in independent 
cross-species transmission events, whereas HIV-1 groups O and P originated from Gorilla 
gorilla gorilla in Cameroon.1  
1.2 Discovery of the Acquired Immune Deficiency Syndrome virus 
In 1981, an editorial in The New England Journal of Medicine pointed out that scientists and 
doctors were puzzled by the fact that many men who sleep with men were suddenly contracting 
rare opportunistic bacterial, fungal and protozoan infections (including: Mycobacterium 
pneumoniae, M. aviumintracellulare, Klebsiella pneumoniae, Candida albicans, Cryptococcus 
neoformans, Pneumocystis carinii, Toxoplasma gondii and Entamoeba histolytica) and 
developing the rare Kaposi’s sarcoma.2 In 1983, two articles were published nearly 
simultaneously that identified the cause of this obscure immunodeficiency to be a retrovirus, 
later termed the human immunodeficiency virus.3-4  
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1.3 HIV replication cycle 
HIV first infects its host using viral membrane-bound envelope (Env) glycoprotein trimers that 
bind to the host cell receptor and chemokine co-receptor, which is commonly CCR5 or CXCR4. 
The viral glycoprotein trimer consists of three heterodimers, each of which contains a 
noncovalently associated transmembrane glycoprotein gp41 and a surface glycoprotein gp120, 
which binds to the host cell receptor.5-6 The viral and host membranes then fuse, and the contents 
of the viral particle are subsequently mixed with the host cells contents, including two single-
stranded RNAs.6  
Once inside the host cell, the viral RNA genome is reverse transcribed into DNA via the virus’s 
reverse transcriptase (RT). RT contains two necessary functions in order to carry out this task: 
DNA polymerase activity, which can copy either a DNA or RNA template, and an RNase H, 
which degrades RNA only if it is forming an RNA-DNA duplex.6-7 Next, the dsDNA is carried 
into the host cells nucleus and integrated into the host cell’s chromosomes through integrase 
(IN), which acts as a multimeric complex.8 The viral genome is then transcribed and translated 
using the host cells proteins. The resulting proteins are inactive gag and gag-pol polyproteins 
that must be further processed to produce mature viral particles; the gag polyprotein precursor 
contains matrix, capsid and p6 domains (as well as the spacers SP1 and SP2), and the gag-pol 
polyprotein precursor additionally contains the viral enzymes protease, reverse transcriptase and 
integrase.9  
The virus then starts to assemble new viral particles inside of the host cell once the gag 
polyprotein has been translated and translocated to an assembly site.9 Assembly occurs at the 
plasma membrane, where Env glycoproteins accumulate; the viral particle is released after gag 
recruits ESCRT, which drives the membrane scission reaction.9  
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Once the viral particles have been released from the host cell, the polyproteins must then be 
cleaved via HIV protease (PR) to form mature infectious viral particles.9-10 
1.4 Historical and current HIV treatments 
In the late 1980’s, zidovudine (AZT) was the first antiretroviral agent to be approved for 
treatment of advanced HIV infection.11-12 AZT is a nucleoside analog, which is converted to its 
active triphosphate form by various intracellular enzymes; once in its active form it binds to 
HIV-1 reverse transcriptase and prevents viral DNA synthesis.11-12 For many years AZT was the 
only antiviral agent available for treatment of those with HIV and AIDS, and when given alone 
to patients with HIV, CD4 counts increased as well as general patient well being.11-12 The 
infection still progressed to AIDS, and the life spans of patients with late-stage AIDS were mere 
months.11-12 It was quickly realized that the benefits of AZT alone were short-lived, and AZT-
resistant strains of HIV-1 were developing.11  
1.4.1 Highly active antiretroviral therapy (HAART) 
In the mid-1990’s doctors began treating patients with HIV-1 with multiple antiviral agents 
with great success.11, 13-15 Protease inhibitors were introduced in 1995, starting with 
saquinavir (SQV).10 This treatment strategy, Highly Active Antiretroviral Therapy 
(HAART), was noted as a turning point in HIV treatment, with a dramatic decrease in HIV 
morbidity and life expectancy improvements.16 HAART is a combination therapy that is 
comprised of at least three drugs from two different classes; typically one protease 
inhibitor or non-nucleoside reverse transcriptase inhibitor, combined with two nucleoside 
reverse transcriptase inhibitors.11, 17 To date, there are antiviral agents that target different 
stages of the viral life cycle: cell entry and fusion, reverse transcription, integration, and 
maturation. While HAART clearly had many advantages, eventually it was uncovered that 
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it came with problems as well; HAART required patients to take upwards of 20 pills a day 
with very specific instructions, and missing even one dose a week could drastically 
increase the chance of the regimen failing.11 Fortunately, HAART is capable of reducing 
viral load, improving immune function and increasing life expectancy.17 
1.5 HIV protease  
HIV PR is a member of the aspartic protease family, and cleaves specific sites in gag and gag-
pol precursor polyproteins, and is essential for viral maturation.18  
 
Figure 1.1 HIV protease mechanism, drawn in ChemDraw. 
 
Rather than recognizing particular amino acid sequences, HIV PR works by recognizing the 
asymmetric shape of the peptide substrates; meaning that all of the cleavage sites have different 
sequences.18 By inhibiting HIV PR, cell-to-cell transmission of the virus is stopped, because HIV 
PR is necessary for viral maturation.19 HIV is able to mutate extremely rapidly because of 
reverse transcriptase lacks a proofreading function, and thus if the levels of antiviral drugs drop, 
then the development of drug resistance is likely.11 Currently there are nine FDA approved 
protease inhibitors (PIs), and unfortunately, resistance mutations have been observed for each of 
these drugs.18, 20  
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1.5.1 General structure of HIV-1 protease 
The active form of HIV-1 PR is a homodimer made of two 99 amino acid subunits, with 
the active site being along the dimer interface and each monomer contributing one of the 
two catalytic aspartates.21 Two β-hairpins cover the active site, and act as highly flexible 
“flaps” that undergo large conformational changes upon binding and release of substrates 
and inhibitors.22  
 
Figure 1.2 Crystal structure of HIV-1 PR in complex with amprenavir.  
 
The crystal structure of 3NU3 is shown in Figure 1.2, modeled in PyMol.23 The protease 
dimer is displayed as cyan ribbons and amprenavir as magenta sticks. The dimer is in a 
closed conformation when bound to substrate or inhibitor, and the flaps open away from 
the catalytic site to allow substrate or inhibitor to enter or be released.10 In WT HIV-1 
PR, three categories of flap conformations have been identified: closed, semi-open, and 
open.24 In resistant mutants, flap dynamics are complex, and it is suggested that altered 
flap flexibility may contribute to drug resistance.24   
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1.5.2 Atazanavir 
 
Figure 1.3. Structure of atazanavir, drawn with ChemDraw. 
Atazanavir (ATV) is a peptidomimetic PI that has been approved in many countries for the 
treatment of adults with HIV-1 infection and in some countries, including the United 
States, children.17 ATV is commonly used as a first-line therapy, and in some cases, ATV 
is administered with a boosting agent, ritonavir, and it is typically administered once 
daily.17, 25 Like other PIs, ATV inhibits the cleavage of gag and gag-pol polyproteins, a 
step that must occur in an ordered fashion, and is essential for viral replication.17, 20 ATV 
resistance profiles have been shown to be distinct from other PIs, and a signature resistance 
mutation has been identified as I50L, which was present in 100% of ATV resistant clinical 
isolates of patients not responding to ATV treatment.17-18 In addition to I50L, the most 
common mutations that have co-emerged for patients using ATV +/- ritonavir include 
L10I/F/V/C, G16E, K20R/M/I/T/V, V32I, L33I/F/V, E34Q, M36I/L/V, M46I/L, G48V, 
F53L/Y, I54L/V/M/T/A, D60E, I62V, I64L/M/V, A71V/I/T/L, G73C/S/T/A, V82A/T/F/I, 
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I84V, I85V, N88S, L90M, and I93L/M.17, 26 Mutations that are specific to patients using 
ATV (+/- ritonavir) are L10C, G16E, K20I/T/V, L33I/V, E34Q, F53Y, D60E, I64L/M/V, 
A71I/L, G73C/T, V82I, I85V, and I93L/M.26 
1.6 HIV-1 protease and drug resistance 
The RT used by HIV-1 during replication has notoriously low fidelity and lacks the ability to 
proofread, with typical retroviral RT error rates thought to be 10-4 to 10-6 errors per nucleotide, 
and is thus thought to be mostly responsible for the virus’s rapid rate of mutation.7, 27 Similar to 
other RNA viruses, HIV is faced with dynamic environments and thus must be a master of 
adaptation, though because of this, it must be careful also not to acquire too many mutations that 
lower viral fitness and push it towards extinction.27 RNA viruses, like HIV, commonly exist as 
quasi-species, with enormous genetic diversity, which consequently allows them to escape 
control rapidly by antiretroviral drugs.7, 28 In addition, the long-term nature of HAART often 
results in loss of adherence to the drug program and allows for the selection of resistant strains.10  
Resistance to PIs is caused by mutations in HIV-1 PR that either alter the inhibitor binding site 
or the dimer interface, while simultaneously retaining the ability to process Gag and Gag-Pol 
polyproteins.10 In addition, Gag cleavage site mutations have also been observed that contribute 
to resistance.25 HIV-1 PR is more susceptible to mutations than any other target of HAART, and 
multiple resistance mutations can be acquired, leading to highly resistant variants.10, 25 “Major” 
resistance mutations of HIV-1 PR decrease binding of PIs, as well as natural substrates, which 
leads to reduced viral replication. “Minor” mutations can improve replication in viruses that 
contain “major mutations”.29  
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1.7 Highly resistant HIV-1 protease variants 
Despite the two newest PIs, darunavir (DRV) and tipranavir, being specifically designed to be 
effective against resistant mutants, PRs that are highly resistant to DRV and other PIs have been 
clinically isolated, leading to an interest in developing strategies to successfully inhibit resistant 
HIV PRs.10 Many possible combinations of mutations in HIV PR are possible and highly 
resistant mutants frequently have 20 or more mutations, with the mutations likely acting 
synergistically in order to evade inhibitors in different fashions.10, 24, 30   
1.7.1 Highly resistant mutant containing 20 mutations (PR20) 
A clinically isolated highly resistant mutant of HIV-1 PR containing 19 mutations (PR20) 
retains its ability to process Gag and Gag-Pol polyproteins, even in the presence of 
current clinical protease inhibitors, although it processes the Gag polyprotein ~4 times 
slower than WT HIV-1 PR while maintaining the same order of cleavage.24, 29, 31 PR20 
contains 15 mutations that are classified as either major or minor drug resistance 
mutations.32 Additionally, PR20 contains three major mutations associated with DRV 
resistance and has an 8,000-fold weaker binding affinity for DRV compared to WT HIV-
1 PR.30 PR20 exhibits a kcat similar to that of wild-type (WT) PR, and PR20 also exhibits 
a Km for a synthetic substrate that is ~13-fold higher relative to WT HIV-1 PR.29 
Additionally, PR20 exhibits a dimer dissociation constant (Kd) that is ~3 fold higher than 
that of WT HIV-1 PR, and uninhibited PR20 exhibits a thermal stability significantly 
greater than WT HIV-1 PR, being that PR20’s Tm is 6°C higher than WT HIV-1 PR.29 
Inhibition of autoprocessing of a 56 amino acid transframe region is not observed for 
PR20, even in the presence of DRV and SQV that exceeds estimated plasma or 
intracellular concentrations.29  
9 
With all of these observations in mind, it is likely that PR20 is clinically unresponsive to 
all current PIs.29 To date, the crystal structures of PR20 without inhibitor, as well as PR20 
in complex with DRV and SQV, have been solved by the Weber lab.29 By comparing the 
crystal structures of PR20 and WT HIV-1 PR, evolving mechanisms of drug resistance 
can be revealed, and strategies for targeting multidrug resistance mutants can potentially 
be improved.29  
1.7.2 Highly resistant mutant containing 15 mutations (PR17) 
PRS17 is another rationally selected clinically isolated highly resistant mutant of HIV-1 
PR that is currently being studied in the Weber lab and contains six mutations in common 
with PR20.30, 33 PRS17 retains its ability to autoprocess, and despite only containing one 
mutation in the substrate-binding cavity, PRS17 is resistant to all clinical inhibitors.30, 33 
The mutations of PRS17 are found in clusters and lack direct interactions with inhibitors.30  
Additionally, despite lacking all of the major mutations associated with DRV resistance, 
PRS17 has a binding affinity for DRV that is 10,000 fold weaker than WT HIV-1 PR, 
suggesting the basis of drug resistance may differ between PR20 and PRS17.30 PRS17 
exhibits a low Kdimer, comparable to WT HIV-1 PR.33 Structural studies of PRS17 in 
complex with DRV revealed that only two G48V and V82S, have contact with DRV, and 
the complex exhibits the closed flap conformation.30 PRS17 in complex with DRV, 
compared to WT HIV-1 PR, exhibits a large conformational change in the hinge loop 
region (residues 34-42), which leads to a loss in the ion pair between E35 and R57 
observed in WT HIV-1 PR.30 It is possible that PRS17 represents a common mechanism of 
drug resistance, and thus it could be a representative model to design inhibitors for drug 
resistant mutants whose resistance is due to distal mutations.30  
10 
2 X-RAY CRYSTALLOGRAPHY AND DRUG DESIGN 
2.1 Current techniques in structural biology 
Current techniques in structural biology include cryo-electron microscopy (cryo-EM), nuclear 
magnetic resonance (NMR), neutron crystallography, and X-ray crystallography.34-36 Cryo-EM is 
a technique that allows for structure determination with near-atomic resolution (~3.5Å) and does 
not require crystallization, which poses a major bottleneck in crystallography techniques.34, 37 
However, using cryo-EM for determining the structure of smaller and dynamic samples remains 
a significant challenge.37 NMR is especially useful in studying protein dynamics, however it has 
intrinsic low sensitivity and thus requires large amounts of protein.38 While there have been 
recent advancements in protein NMR methods; it is typically quite difficult to study large 
proteins, or those with a mass above 30 kDa.38 Despite a few fundamental limitations (protein 
crystallization, unresolved dynamics, and limited detection of chemical heterogeneity), X-ray 
crystallography has remained the primary method of 3-D structure determination of proteins, 
viruses and nucleic acids, and structures determined by X-ray crystallography continue to be the 
majority of structures deposited in the PDB.34, 39     
2.2 Why use X-ray crystallography? 
X-ray crystallography is the central experimental technique used in structure-assisted drug 
design because structure solution and refinement are becoming increasingly more automated and 
newer synchrotrons allow for diffraction data to be collected rapidly and with high resolution 
from small crystals.34, 36, 38 Furthermore, resolution of the diffraction data for a structure is an 
important parameter to consider, especially when using a structure for drug-design, because the 
atomic coordinates of a 1.5 Å structure are much more reliable than that of a structure with 3.5 Å 
resolution.40 Unfortunately, structures in the PDB may contain errors, which can be problematic 
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for structure-guided drug design, specifically with structures that contain errors in the modeling 
of ligands in protein-ligand complexes.34  
2.3 Structure-guided drug design and HIV-1 PR 
Structure-guided drug design uses structure determination techniques (such as X-ray 
crystallography or NMR) and computational biology to guide the synthesis of drugs.41 Structural 
studies of HIV-1 PR in complex with various inhibitors have been important in drug design; 
however, they have also historically been complemented with computational studies, such as 
docking and molecular dynamics, to understand the mode of inhibitor binding, and for 
optimization of inhibitor design.41 Inhibitors of HIV-1 PR have been designed to maximize 
interactions with the enzymes backbone in the active site, which has led to potent FDA approved 
inhibitors with high barriers to resistance.42 Analysis of crystal structures of WT HIV-1 PR in 
complex with DRV, as well as mutant PRs, have shown extensive hydrogen bonding between the 
PR backbone and inhibitor.42 This suggests that designing inhibitors with increased interactions 
with the WT HIV-1 PR backbone will likely retain potency against mutant strains due to their 
lack of the ability to eliminate inhibitor-backbone interactions.42    
2.3.1 The importance of atomic resolution 
X-ray crystal structures can potentially reveal the locations of H atoms typically around 1 
Å resolution, which is extremely important in structure-guided drug design, because H 
atoms play critical roles in H-bonding, electrostatic interactions and catalysis.35, 42  
2.4 Protein crystallization 
To solve the crystal structure of a protein (or DNA, small molecule, etc.), first a crystal must be 
formed. To achieve this a solution of protein is manipulated to induce supersaturation of the 
protein to produce protein crystals. There are three main methods to produce crystals: vapor-
12 
diffusion, liquid-diffusion and batch, however for this work only vapor-diffusion was used. 
Vapor-diffusion can be further divided into hanging-drop and sitting-drop methods. In vapor-
diffusion methods, a protein solution is mixed with a reservoir solution to form a small drop, 
which is typically just a few µL, and the drop is placed on a surface. The droplet is then sealed 
inside an airtight chamber, along with the reservoir solution. The droplet and the reservoir 
solution undergo a dynamic equilibration until the drop and the reservoir together reach a state of 
equilibrium.  
 
Figure 2.1 Simplified phase diagram for crystallization of proteins, created in 
ChemDraw. 
The goal is for the protein to exceed its solubility limit, in the metastable zone, and not 
precipitate, but instead form crystals.43 There is no way to predict what conditions will achieve 
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this goal, but fortunately there are many kits that assess a wide array of crystallization 
conditions, assisting one in determining what conditions to start with.39, 43  
2.5 X-ray diffraction, data processing and refinement 
Once crystallization conditions have been optimized to produce crystals that are seemingly 
worthy of diffraction, the crystal is fished into a loop and frozen, and then X-ray data can be 
collected using either a home source, or an X-ray beam generated by a synchrotron.44 Typically, 
a synchrotron is preferred over a home source, due to the higher quality of data that it can yield.44 
During data collection, the crystal is rotated, and many frames of diffracted X-rays are collected 
on a detector.45 Each reflection provided on the diffraction map is characterized both by its 
amplitude and phase; the peak intensities can provide amplitudes, but the reflection does not 
provide any direct information about the phase.39 The phase of light cannot be directly measured, 
so to solve the structure, the phase problem must be addressed.45 While there are a few ways to 
approach the phase problem, in the case of HIV-1 protease, many high-quality structures are 
available, so the molecular replacement method can easily be employed to solve this problem (in 
fact, this method has been used for nearly 80% of structures deposited in the PDB).39, 46 Once the 
phase problem has been addressed an electron density map can be produced, which can then be 
refined (varying model parameters to achieve similarity between observed and calculated 
reflection amplitudes) and fit to solve the crystal structure.47       
2.6 Currently available structures of HIV-1 PR and ATV complex 
Prior to this study, there were three structures of other groups’ HIV-1 PRs in complex with ATV 
available in the protein data bank (PDB), however these structures are considered to have 
moderate resolution (Table 1) compared to what has been recently achievable with HIV-1 PR in 
the Weber lab, and the WT sequences are not identical (Figure 2.2) to that of the Weber lab.48-49 
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Additionally, the three current structures have differences between the conformation(s) of ATV. 
It is important to note that proteases studied in the Weber lab have optimizing mutations, Q7K, 
L33I, and L63I, to increase protein stability and C67A and C95A to prevent the formation of 
disulfide bonds.23 Other sequences differences are presumed to be polymorphisms. 
PDB ID Resolution (Å) Space group Rfree Rwork 
2AQU 2.0 P61 0.238 0.227 
3EKY 1.8 P212121 0.209 0.176 
3EL1 1.7 P212121 0.205 Not provided 
Table 1. Crystallographic data for crystal structures of WT HIV-1 PR available in PDB.  
 
 
Figure 2.2 Multiple sequence alignment of sequences from other WT HIV-1 PR structures 
currently available in the PDB. 
 
2.7 Benefits of protease – inhibitor atomic resolution structures 
By solving an atomic resolution structure of WT HIV-1 PR in complex with ATV, more accurate 
comparisons of drugs interacting with WT HIV-1 PR can be made between ATV and DRV. 
Additionally, the interactions between ATV and highly drug resistant mutants can be compared 
with interactions in WT HIV-1 PR. By comparing these interactions in both WT and highly drug 
resistant mutants, more insight can be provided into designing drugs that are more potent against 
highly drug resistant mutants.  
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3 EXPERIMENT 
Using Escherichia coli cells, HIV-1 protease was expressed in inclusion bodies, which were 
cleaned and HIV-1 PR was purified using gel filtration chromatography and high performance 
liquid chromatography. The PR was then dialyzed and refolded. The pure protein was then used 
to produce crystals in complex with ATV, and X-ray diffraction patterns were collected at a 
synchrotron, and the data was used to solve the structure of WT HIV-1 PR in complex with ATV 
structure with 1.09 Å resolution.  
3.1 Purification of HIV-1 Protease 
3.1.1 HIV-1 protease overexpression 
Using BL21(DE3) cells harboring a plasmid containing the gene for HIV-1 PR, a 100 mL 
culture of pre-innoculum cells was grown in Luria Bertani (LB) broth containing 100 
mg/ml carbenicillin. 10 mL of pre-innoculum was used to inoculate four 1 L flasks of LB 
broth containing 100 mg/mL carbenicillin. The cultures were grown at 37°C at 200 rpm to 
an OD of 0.6-0.8 when they were then induced with a final concentration of 2 mM 
isopropyl β-D-1-thiogalactopyranoside. The cultures were grown for 4 hours after 
induction and were then centrifuged at 5,000 rpm for 20 minutes at 4°C. The cells pellets 
were then stored at -80°C until further use. 
3.1.2  HIV-1 protease inclusion body processing 
The pellets were homogenized in 20 mL/1g cell pellet sonication buffer (50 mM tris pH 8.0, 10 
mM EDTA pH 8.0, 1 mg/mL Lysozyme).  200 µL Triton-X 100 was added per 20 mL 
sonication buffer, and the cells were stirred for 2 hours. The cells were then sonicated on ice 
six times for 1 minute with 2 minute breaks. The cells were then centrifuged at 12,000 rpm 
4°C for 20 min, the supernatant was discarded, and the pellet was resuspended in buffer B (50 
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mM tris mM, 10 mM EDTA pH 8.0, 2 M urea). The cells were then centrifuged again at 
12,000 rpm, 4°C for 20 minutes and the pellet was resuspended again in buffer B. The cells 
were then centrifuged again at 12,000 rpm, 4°C for 20 minutes and the pellet was resuspended 
in buffer A (50 mM tris pH 8.0, and 20 mM EDTA pH 8.0). The cells were then centrifuged 
again at 12,000 rpm, 4°C for minutes. The pellet was resuspended in 10 mM DTT and stored at 
-20°C until further use.  
3.1.3 Gel Filtration Chromatography 
HiLoadTM 26/600 SuperdexTM 75 pg size exclusion column was washed with two column 
volumes of degassed deionized water, and again with two column volumes of gel filtration 
buffer (3 M guanidine HCl, 50 mM Tris pH 8.0, 5 mM EDTA pH 8.0, 5 mM DTT). The 
inclusion bodies were thawed in a water bath and centrifuged at 12,000 rpm for 20 minutes at 
4°C. The pellet was resuspended in 8 M guanidine HCl, 10 mM DTT and mixed for 1 hour. 
The solution was then filtered with a 0.8 micron filter. The sample was then injected into the 
column and run with a flow rate of 2.000 mL/min. The HIV-1 PR peak was collected and 
pooled and stored at -20°C for further use. 
3.1.4 High-Performance Liquid Chromatography 
HPLC column was equilibrated with two column volumes of 0.05% trifluoroacetic acid. The 
HPLC column was loaded with 5 mL gel filtration fractions and run with a flow rate of 1.000 
mL/min. The protease eluted at 30% acetonitrile/70% water/0.05% trifluoroacetic acid. The 
HIV-1 PR peak was collected and pooled and stored at -20°C for further use. 
3.1.5 Dialysis and refolding 
The HPLC fractions were injected into a Slide-A-LyzerTM dialysis cassette and incubated in 2 
L 25 mM formic acid/1 mM DTT overnight at 4°C. The cassette was then transferred to 50 
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mM sodium acetate pH 5.0 at 4 °C for 4 hours. The protein was then concentrated by 
centrifugation, and the protein concentration was determined by absorbance at 280 nm. 
3.2 Crystallization of HIV-1 protease in complex with atazanavir  
3.2.1 Initial crystallization screening 
Crystallographic conditions were screened using Hampton Research Crystal ScreenTM 
HR2-112 kit and the hanging drop vapor diffusion method. The crystallization drops 
consisted of 1 µL of 4.2 mg/mL HIV-1 PR/2mM ATV and 1 µL reservoir solution.   
3.2.2 Crystallization for X-ray diffraction 
Four of the most promising conditions from the screening kit that produced crystals were 
further explored. Optimization involved varying concentrations of the screening reagents 
and the pH of the buffers. The HIV-1 PR and ATV concentration, temperature and 
hanging drop vapor diffusion method remained the same.  
3.3 X-ray Data Collection and Structure Refinement 
X-ray diffraction data was collected on ID beamline of the Southeast Regional Collaborative 
Access Team (SER-CAT) at the Advanced Photon Source at Argonne National Laboratory. The 
diffraction data was scaled and integrated with HKL2000, and the HIV-1 PR in complex with 
ATV structure was solved by molecular replacement with the HIV-1 PR in complex with 
amprenavir (3NU3) as the starting model by PHASER and CCP4.50-52 The structure was refined 
using SHELX-2014 and model building was carried out using Coot, and anisotropic B factor 
refinement was applied.53-54  
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4 RESULTS 
HIV-1 protease was purified from inclusion bodies using gel filtration chromatography and high-
performance liquid chromatography and was dialyzed, refolded and concentrated. The protease 
was then crystallized using hanging drop vapor diffusion, and X-ray diffraction patterns were 
collected for numerous crystals. The highest quality diffraction data was used to solve the HIV-1 
in complex with ATV by molecular replacement, using 3NU3 as a model.   
4.1 HIV protease purification 
4.1.1 Gel filtration chromatography of HIV protease 
HIV-1 protease inclusion bodies were washed and dissolved in 5 mL 8 M guanidine HCl 
10 mM DTT and injected into the gel filtration column and ran with a flow rate of 2.000 
mL/min. The protein eluted in fractions 24-34 (Figure 4.1) and had a λmax280 = 200 mAU. 
In Figure 4.1, the x-axis represents mL, and the y-axis represents mAU.  
 
Figure 4.1 Gel filtration chromatogram of HIV protease. 
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4.1.2 HPLC of HIV protease 
The resulting protein fractions from gel filtration chromatography were pooled and 
injected into the HPLC, which was run with a flow rate of 1.000 mL/min. The protease 
eluted at 30% acetonitrile/70% water/0.05% trifluoroacetic acid in fractions 10 – 15 
(Figure 4.2) and the protein peaks had a λmax280 = 290 mAU. In Figure 4.2, the x-axis 
represents mL and the y-axis represents mAU.  
 
Figure 4.2 High performance liquid chromatogram of HIV protease. 
 
4.1.3 Dialysis, refolding, and concentration of HIV-1 PR  
HIV-1 PR was dialyzed and subsequently refolded by placing it in a solution of acetic acid 
at its active pH, 5.0, for ~4 hours. The protein was concentrated by centrifuging, and the 
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concentration was determined to be 8.4 mg/mL based on its absorbance at 280 nm. The 
HIV-1 PR was determined to be active via a fluorescence activity assay that involves 
cleaving of an artificial peptide substrate (of which the fluorescence is otherwise 
quenched).  
4.2 Crystallization and data collection 
4.2.1 Crystal optimization 
After analyzing X-ray diffraction patterns from various crystals, it was determined that the 
crystal grown under the following conditions produced the highest resolution diffraction 
pattern: 0.1 M sodium cacodylate pH 6.0, 0.2 M magnesium acetate, and 16% PEG 8000. 
4.2.2 X-ray diffraction 
The crystal with the highest resolution diffraction diffracted at 1.09 Å and belonged to the 
space group P21212. The diffraction pattern of this crystal was clean and well defined and was 
used to successfully determine the structure of HIV-1 PR in complex with ATV. The data 
collection statistics are summarized in Table 2.  
Space group P21212 
Unit cell dimensions (Å)  
α 58.72 
β 85.79 
γ 46.58 
Resolution range (Å) 50-1.09 (1.13-1.09) 
Unique reflections 91524 (5026) 
Rmerge (%) 7.8 (29.6) 
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I/σ (I) 28.1 (3.3) 
Completeness (%) 92.9 (51.6) 
Redundancy  6.4 (2.3) 
Refinement  
 R (%) 14.7 
 Rfree (%) 17.4 
Solvent molecules (total occupancies) 269 (209.7) 
  1 Cl- + 2 GOL + 1 CAC + 251 H2O 
RMS deviation from ideality  
 Bonds (Å) 0.0153 
 Angle distance (Å) 0.0350 
Average B-factors (Å2)  
 Wilson Plot B factor 7.9 
 Main-chain atoms 10.9 
 Side-chain atoms 16.2 
 Whole chain atoms 13.5 
 ATV 9.9 
 Solvent 23.8 
RMS deviation to DRV (2IEN) (Å) 0.29 
Table 2. X-ray diffraction data-collection and model-refinement statistics.  
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4.3 Analysis of HIV-1 atazanavir complex structure 
The crystallography asymmetric units contain a HIV-1 PR dimer with the residues of the subunits 
numbered 1-99 and 100-199. Excellent electron density was shown for all protease atoms, ATV and 
solvent molecules.  
4.3.1 RMSD between HIV-1 PR atazanavir complex and darunavir complex 
 
 
Figure 4.3. RMSD between WT HIV-1 PR in complex with atazanavir and WT HIV-1 PR 
in complex with darunavir. 
 
Root-mean-square deviation (RMSD) values between WT HIV-1 PR in complex with ATV and 
WT HIV-1 PR in complex with DRV for chain A are displayed in the top, and RMSD values for 
chain B are displayed on the bottom. 
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4.3.2 Alternate conformations 
Alternate conformations were modeled for 19 residues (Chain A – K7, E21, K45, I50, G51, I63, A71, 
V82, I84, L97 Chain B – K114, V132, S137, M146, I150, G151, Q161, E165, L197) in the crystal 
structure, as well as two conformations of atazanavir (Figure 4.7). The relative occupancy of the 
ATV conformations is 0.70/0.30. The residues with alternate conformations were not the same in 
both subunits, aside from I50/I150, G51/G151 and L97/L197, in which alternate conformations were 
modeled for both subunits (Figures 4.5 and 4.6). Clear electron density for was present for both 
conformations of the residues. 2F0-Fc electron density maps were used for all comparisons and all 
σ levels are set to 1.50 for each map in Figures 4.4-4.8. 
 
Figure 4.4 Electron density map of active site aspartates interacting with ATV 
 
24 
 
Figure 4.5 Electron density map displaying multiple conformations of L97 (left) and L197 (right) 
25 
 
Figure 4.6 Alternate conformations of I50 and G51 (top) and I150 and G151 (bottom) 
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Figure 4.7 Electron density map displaying multiple atazanavir conformations 
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4.3.3 Solvent structures 
The high quality data allowed for modeling of a second shell of solvent, with over 200 water 
molecules included in the model, some with partial occupancy. Additionally, chloride was 
modeled, and glycerol and cacodylate were fitted to the density (examples are shown in Figure 
4.8).  
 
Figure 4.8 Electron density map of cacodylate (left) and glycerol (right) 
4.4 Comparison of multiple conformations with published structures 
2AQU modeled multiple conformations for K43, I47, I64, and ATV; 2AQU also reported 0.50 
occupancy of I15, however no second conformation. Aside from ATV, none of these alternate 
conformations are the same as in the Weber WT structure.  
3EL1 modeled multiple conformations for M46, I50, G51, V75, C95, I150, G151, C167, and 
ATV. M46, I50, G51, I150, and ATV also had multiple conformations in the Weber WT 
structure. However, V75, C95, and C167 did not exhibit multiple conformations in the Weber 
WT structure.  
4.5 Comparison of atazanavir density with published structures 
The ATV ligands from 3EL1 and 2AQU were superimposed with the ATV of the Weber WT 
HIV-1 PR in complex with ATV structure. 3EK1 was not used for comparisons, as it was 
published in conjunction with 3EL1. It is the same space group (P212121) but displays one 
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conformation of ATV, rather than two like all of the other structures. Additionally, 3EL1 is 
slightly higher resolution than 3EKY (1.7 and 1.8 Å respectively), and the electron density map 
is clearly higher quality than 3EKY.  
The ATV from the Weber WT structure is displayed in green, 3EL1 in pink, and 2AQU in teal. 
The superimposition of ATV shows that the ATV conformation modeled in 3EL1 differs fairly 
significantly from that of 2AQU and the Weber WT structure.  
 
Figure 4.9 Superimposition of atazanavir of 2AQU, 3EL1 and Weber WT structure 
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Figure 4.10 Electron density map of ATV from Weber WT structure 
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Figure 4.11 Electron density map of ATV from 3EL1. 
 
Figure 4.12 Electron density map of ATV from 2AQU 
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2F0-Fc electron density maps were used and all σ levels are set to 1.50 for each map in Figures 
4.10-12. 2AQU and 3EL1 have also modeled alternate conformations of ATV; however, the 
occupancy of each conformation is 0.50/0.50 in each structure, whereas in the Weber WT 
structure, the occupancy is 0.70/0.30. The higher resolution Weber WT structure displays clear 
density for the major conformation of ATV and slightly less well-defined density for the minor 
conformation of ATV (Figure 4.10). Both 2AQU and 3EL1 show nearly no electron density for 
the terminal rings of ATV as seen in Figures 4.11 and 4.12.  
 
4.6 Comparison of protease-inhibitor interactions 
Protease-inhibitor interactions were compared between the ATV complex, and a previously 
reported DRV complex (PDB ID: 2IEN).55 For both structures inhibitor was modeled in two 
conformations. However, when comparing the structures, only the major conformation was 
considered. The relative occupancy in the ATV complex is 0.70/0.30, and the relative occupancy 
of the DRV complex is 0.55/0.45. Hydrogen bonds between inhibitor and protease or solvent are 
demonstrated in Figure 4.15 and Figure 4.16.  
The major conformation of ATV forms hydrogen bonds with the side chains of D25, D125, and 
D129 and the backbone of D29, G27, G127, and G148, as well as numerous waters. The major 
conformation of DRV forms hydrogen bonds with the side chains of D25, D30, and D125 and 
the backbone of G127, D129, and D130, in addition to waters. While ATV forms hydrogen 
bonds with the N in the amide of the D129 backbone, it does not form hydrogen bonds with 
D130, which attributes to the high barrier of resistance displayed by DRV.42  
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4.6.1 Hydrogen bonding comparison between HIV-1 PR atazanavir complex and darunavir 
complex 
 
Figure 4.13 Interactions between ATV and HIV-1 PR, drawn in ChemDraw. 
 
 
Figure 4.14 Interactions between DRV and HIV-1 PR, drawn in ChemDraw. 
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5 CONCLUSIONS 
WT HIV-1 PR was expressed in inclusion bodies in E. coli, and purified using gel filtration 
chromatography and HPLC. The PR was then dialyzed, refolded, and concentrated by 
centrifugation, and then the protein was determined to be active using an enzymatic assay with 
an artificial peptide substrate. WT HIV-1 PR in complex with ATV was crystallized, and 
crystallization conditions producing the highest resolution diffraction patterns were determined 
to be: 0.1 M sodium cacodylate pH 6.0, 0.2 M magnesium acetate, and 16% PEG 8000. The structure 
of the WT HIV-1 PR in complex with ATV structure was solved with a resolution of 1.09 Å. 
Multiple conformations of 19 side chains were modeled. The structure indicates that ATV forms 
hydrogen bonds with three side chains and four hydrogen bonds with the PR backbone. Additionally, 
the high quality electron density map allowed for two conformations of ATV to be modeled (with 
occupancies of 0.70/0.30). This atomic resolution structure of HIV-1 PR in complex with ATV can 
be used to make comparisons of future crystal structures of highly drug resistant mutants in complex 
with atazanavir to provide insights to mechanisms of drug resistance, as well as provide insight to 
create new protease inhibitors with high barriers to resistance.  
 
  
34 
REFERENCES 
1. Hemelaar, J., The origin and diversity of the HIV-1 pandemic. Trends Mol Med 2012, 18 
(3), 182-92. 
2. Durack, D. T., Opportunistic infections and Kaposi's sarcoma in homosexual men. N 
Engl J Med 1981, 305 (24), 1465-7. 
3. Broder, S.; Gallo, R. C., A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J 
Med 1984, 311 (20), 1292-7. 
4. Barre-Sinoussi, F.; Chermann, J.; Rey, F.; Nugeyre, M.; Chamaret, S.; Gruest, J.; 
Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L., 
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency 
syndrome (AIDS). Science 1983, 220 (4599), 868-871. 
5. Brandenberg, O. F.; Magnus, C.; Regoes, R. R.; Trkola, A., The HIV-1 Entry Process: A 
Stoichiometric View. Trends Microbiol 2015, 23 (12), 763-774. 
6. Hu, W. S.; Hughes, S. H., HIV-1 reverse transcription. Cold Spring Harb Perspect Med 
2012, 2 (10). 
7. Lloyd, S. B.; Kent, S. J.; Winnall, W. R., The high cost of fidelity. AIDS Res Hum 
Retroviruses 2014, 30 (1), 8-16. 
8. Esposito, F.; Tramontano, E., Past and future. Current drugs targeting HIV-1 integrase 
and reverse transcriptase-associated ribonuclease H activity: single and dual active site 
inhibitors. Antivir Chem Chemother 2014, 23 (4), 129-44. 
9. Freed, E. O., HIV-1 assembly, release and maturation. Nat Rev Microbiol 2015, 13 (8), 
484-96. 
35 
10. Weber, I. T.; Kneller, D. W.; Wong-Sam, A., Highly resistant HIV-1 proteases and 
strategies for their inhibition. Future Med Chem 2015, 7 (8), 1023-38. 
11. Peters, B. S.; Conway, K., Therapy for HIV: past, present, and future. Adv Dent Res 
2011, 23 (1), 23-7. 
12. Rachlis, A. R., Zidovudine (Retrovir) update. CMAJ 1990, 143 (11), 1177-85. 
13. Montaner, J. S. G.; Reiss, P.; Cooper, D.; Vella, S.; Harris, M.; Conway, B.; Wainberg, 
M. A.; Smith, D.; Robinson, P.; Hall, D.; Myers, M.; Lange, J. M. A.; for the, I. S. G., A 
Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and 
Zidovudine for HIV-Infected Patients. Jama 1998, 279 (12). 
14. Gulick, R. M.; Mellors, J. W.; Havlir, D.; Eron, J. J.; Gonzalez, C.; McMahon, D.; 
Richman, D. D.; Valentine, F. T.; Jonas, L.; Meibohm, A.; Emini, E. A.; Chodakewitz, J. A., 
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency 
virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337 (11), 734-9. 
15. Hogg, R. S.; Yip, B.; Kully, C.; Craib, K. J. P.; O'Shaughnessy, M. V.; Schechter, M. T.; 
Montaner, J. S. G., Improved survival among HIV-infected patients after initiation of triple-drug 
antiretroviral regimens. Canadian Medical Association Journal 1999, 160 (5), 659-665. 
16. Olding, M.; Enns, B.; Panagiotoglou, D.; Shoveller, J.; Harrigan, P. R.; Barrios, R.; Kerr, 
T.; Montaner, J. S. G.; Nosyk, B., A historical review of HIV prevention and care initiatives in 
British Columbia, Canada: 1996-2015. J Int AIDS Soc 2017, 20 (1), 21941. 
17. Croom, K. F.; Dhillon, S.; Keam, S. J., Atazanavir: a review of its use in the management 
of HIV-1 infection. Drugs 2009, 69 (8), 1107-40. 
18. Wensing, A. M.; van Maarseveen, N. M.; Nijhuis, M., Fifteen years of HIV Protease 
Inhibitors: raising the barrier to resistance. Antiviral Res 2010, 85 (1), 59-74. 
36 
19. Titanji, B. K.; Aasa-Chapman, M.; Pillay, D.; Jolly, C., Protease inhibitors effectively 
block cell-to-cell spread of HIV-1 between T cells. Retrovirology 2013, 10, 161. 
20. I.T., W.; R.W., H., Tackling the problem of HIV drug resistance. Postępy Biochemii 62 
(3), 273-279. 
21. Louis, J. M.; Ishima, R.; Torchia, D. A.; Weber, I. T., HIV-1 protease: structure, 
dynamics, and inhibition. Adv Pharmacol 2007, 55, 261-98. 
22. Erickson, J. W.; Burt, S. K., Structural mechanisms of HIV drug resistance. Annu Rev 
Pharmacol Toxicol 1996, 36, 545-71. 
23. Shen, C. H.; Wang, Y. F.; Kovalevsky, A. Y.; Harrison, R. W.; Weber, I. T., Amprenavir 
complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters. 
FEBS J 2010, 277 (18), 3699-714. 
24. Shen, C. H.; Chang, Y. C.; Agniswamy, J.; Harrison, R. W.; Weber, I. T., 
Conformational variation of an extreme drug resistant mutant of HIV protease. J Mol Graph 
Model 2015, 62, 87-96. 
25. Shafer, R. W.; Schapiro, J. M., HIV-1 drug resistance mutations: an updated framework 
for the second decade of HAART. AIDS Rev 2008, 10 (2), 67-84. 
26. Wensing, A. M.; Calvez, V.; Gunthard, H. F.; Johnson, V. A.; Paredes, R.; Pillay, D.; 
Shafer, R. W.; Richman, D. D., 2017 Update of the Drug Resistance Mutations in HIV-1. Top 
Antivir Med 2017, 24 (4), 132-133. 
27. Lauring, A. S.; Frydman, J.; Andino, R., The role of mutational robustness in RNA virus 
evolution. Nat Rev Microbiol 2013, 11 (5), 327-36. 
28. Yin, L.; Liu, L.; Sun, Y.; Hou, W.; Lowe, A. C.; Gardner, B. P.; Salemi, M.; Williams, 
W. B.; Farmerie, W. G.; Sleasman, J. W.; Goodenow, M. M., High-resolution deep sequencing 
37 
reveals biodiversity, population structure, and persistence of HIV-1 quasispecies within host 
ecosystems. Retrovirology 2012, 9, 108. 
29. Agniswamy, J.; Shen, C. H.; Aniana, A.; Sayer, J. M.; Louis, J. M.; Weber, I. T., HIV-1 
protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated 
structural rearrangements. Biochemistry 2012, 51 (13), 2819-28. 
30. Agniswamy, J.; Louis, J. M.; Roche, J.; Harrison, R. W.; Weber, I. T., Structural Studies 
of a Rationally Selected Multi-Drug Resistant HIV-1 Protease Reveal Synergistic Effect of 
Distal Mutations on Flap Dynamics. PLoS One 2016, 11 (12), e0168616. 
31. Louis, J. M.; Deshmukh, L.; Sayer, J. M.; Aniana, A.; Clore, G. M., Mutations Proximal 
to Sites of Autoproteolysis and the alpha-Helix That Co-evolve under Drug Pressure Modulate 
the Autoprocessing and Vitality of HIV-1 Protease. Biochemistry 2015, 54 (35), 5414-24. 
32. Johnson, V. A.; Brun-Vezinet, F.; Clotet, B.; Gunthard, H. F.; Kuritzkes, D. R.; Pillay, 
D.; Schapiro, J. M.; Richman, D. D., Update of the drug resistance mutations in HIV-1: 
December 2010. Top HIV Med 2010, 18 (5), 156-63. 
33. Park, J. H.; Sayer, J. M.; Aniana, A.; Yu, X.; Weber, I. T.; Harrison, R. W.; Louis, J. M., 
Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant 
HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme. 
Biochemistry 2016, 55 (16), 2390-400. 
34. Zheng, H.; Handing, K. B.; Zimmerman, M. D.; Shabalin, I. G.; Almo, S. C.; Minor, W., 
X-ray crystallography over the past decade for novel drug discovery - where are we heading 
next? Expert Opin Drug Discov 2015, 10 (9), 975-89. 
38 
35. Chen, J. C.; Hanson, B. L.; Fisher, S. Z.; Langan, P.; Kovalevsky, A. Y., Direct 
observation of hydrogen atom dynamics and interactions by ultrahigh resolution neutron protein 
crystallography. Proc Natl Acad Sci U S A 2012, 109 (38), 15301-6. 
36. Weber, I. T.; Waltman, M. J.; Mustyakimov, M.; Blakeley, M. P.; Keen, D. A.; Ghosh, 
A. K.; Langan, P.; Kovalevsky, A. Y., Joint X-ray/neutron crystallographic study of HIV-1 
protease with clinical inhibitor amprenavir: insights for drug design. J Med Chem 2013, 56 (13), 
5631-5. 
37. Binshtein, E.; Ohi, M. D., Cryo-electron microscopy and the amazing race to atomic 
resolution. Biochemistry 2015, 54 (20), 3133-41. 
38. Wang, G.; Zhang, Z. T.; Jiang, B.; Zhang, X.; Li, C.; Liu, M., Recent advances in protein 
NMR spectroscopy and their implications in protein therapeutics research. Anal Bioanal Chem 
2014, 406 (9-10), 2279-88. 
39. Wlodawer, A.; Minor, W.; Dauter, Z.; Jaskolski, M., Protein crystallography for aspiring 
crystallographers or how to avoid pitfalls and traps in macromolecular structure determination. 
FEBS J 2013, 280 (22), 5705-36. 
40. Zheng, H.; Hou, J.; Zimmerman, M. D.; Wlodawer, A.; Minor, W., The future of 
crystallography in drug discovery. Expert Opin Drug Discov 2014, 9 (2), 125-37. 
41. Wlodawer, A., Rational approach to AIDS drug design through structural biology. Annu 
Rev Med 2002, 53, 595-614. 
42. Ghosh, A. K.; Chapsal, B. D.; Weber, I. T.; Mitsuya, H., Design of HIV protease 
inhibitors targeting protein backbone: an effective strategy for combating drug resistance. Acc 
Chem Res 2008, 41 (1), 78-86. 
39 
43. Luft, J. R.; Newman, J.; Snell, E. H., Crystallization screening: the influence of history 
on current practice. Acta Crystallogr F Struct Biol Commun 2014, 70 (Pt 7), 835-53. 
44. Jain, D.; Lamour, V., Computational tools in protein crystallography. Methods Mol Biol 
2010, 673, 129-56. 
45. MS, S.; JHJ, M., x Ray crystallography. Molecular Pathology 2000, 53 (1), 8-14. 
46. Bunkoczi, G.; Echols, N.; McCoy, A. J.; Oeffner, R. D.; Adams, P. D.; Read, R. J., 
Phaser.MRage: automated molecular replacement. Acta Crystallogr D Biol Crystallogr 2013, 69 
(Pt 11), 2276-86. 
47. Wlodawer, A.; Minor, W.; Dauter, Z.; Jaskolski, M., Protein crystallography for non-
crystallographers, or how to get the best (but not more) from published macromolecular 
structures. FEBS J 2008, 275 (1), 1-21. 
48. Clemente, J. C.; Coman, R. M.; Thiaville, M. M.; Janka, L. K.; Jeung, J. A.; Nukoolkarn, 
S.; Govindasamy, L.; Agbandje-McKenna, M.; McKenna, R.; Leelamanit, W.; Goodenow, M. 
M.; Dunn, B. M., Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural 
determinants for maintaining sensitivity and developing resistance to atazanavir. Biochemistry 
2006, 45 (17), 5468-77. 
49. King, N. M.; Prabu-Jeyabalan, M.; Bandaranayake, R. M.; Nalam, M. N.; Nalivaika, E. 
A.; Ozen, A.; Haliloglu, T.; Yilmaz, N. K.; Schiffer, C. A., Extreme entropy-enthalpy 
compensation in a drug-resistant variant of HIV-1 protease. ACS Chem Biol 2012, 7 (9), 1536-
46. 
50. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; 
Read, R. J., Phaser crystallographic software. J Appl Crystallogr 2007, 40 (Pt 4), 658-674. 
40 
51. Z., O.; W., M., Processing of X-ray diffraction data collected in oscillation mode. Meth. 
Enzymol. 1997, 276, 307-26. 
52. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J., Refinement of macromolecular structures 
by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997, 53 (Pt 3), 240-
55. 
53. Emsley, P.; Cowtan, K., Coot: model-building tools for molecular graphics. Acta 
Crystallogr D Biol Crystallogr 2004, 60 (Pt 12 Pt 1), 2126-32. 
54. Sheldrick, G. M., Crystal structure refinement with SHELXL. Acta Crystallogr C Struct 
Chem 2015, 71 (Pt 1), 3-8. 
55. Tie, Y.; Boross, P. I.; Wang, Y. F.; Gaddis, L.; Hussain, A. K.; Leshchenko, S.; Ghosh, 
A. K.; Louis, J. M.; Harrison, R. W.; Weber, I. T., High resolution crystal structures of HIV-1 
protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant 
clinical strains. J Mol Biol 2004, 338 (2), 341-52. 
 
